National Health Alliance Panel: Centering Patient Needs in Value-Based Oncology
Considering patient needs in oncology care means thinking beyond just health outcomes, according to a panel of oncology experts speaking [...]
Breaking Down the New NHS Value Proposition
With the growing influence of Integrated Care Systems (ICS) in the UK, the NHS has adjusted their definition of value. [...]
Value in Health Regional Issues: Quantifying the Societal Benefits of Telehealth
Telehealth has seen a massive spike in utilization during the COVID-19 pandemic, but questions remain as to its economic value [...]
ISPOR 2022 – Paying for Digital Therapeutics (DTx): What Evidence Is Needed?
There is currently no consensus between stakeholders on the value of DTx, or software-based approaches to treatment or prevention of [...]
Value-Based Healthcare Services Market Report for 2022-2029
A2Z Market Research has released a new report detailing its projections for the worldwide value-based healthcare services market. This report [...]
Over 700 Hospitals Facing Penalties from HAC Reduction Program
764 hospitals across the US will face penalties in 2022 due to not meeting value-based standards set by Medicare’s Hospital-Acquired [...]
Scientist.com Webinar: Expediting the Sourcing of Value, Access, and Evidence Sources
In a new on-demand webinar, a panel from Scientist.com discuss how marketplaces can accelerate science, especially in the fields of [...]
AMCP Releases Pay-for-Performance Principles for Pharmacists
The Academy of Managed Care Pharmacy (AMCP) has released its list of 13 principles for an ethical and effective pay-for-performance [...]
JAMA Health Forum Study Finds Physicians Compensated for Volume, not Value
Despite a push by payers to move to value-based compensation, a new study shows that physicians are paid based largely [...]
ICER Releases Draft Report on Plinabulin and Trilaciclib for Chemo-induced Neutropenia
The Institute for Clinical and Economic Review (ICER) has released its draft evidence report for the novel drugs plinabulin (BeyondSpring [...]
ICER Releases Evidence Report for Type 2 Diabetes Drug Tirzepatide
The Institute for Clinical and Economic Review (ICER) has released their revised evidence report for Eli Lilly’s new type 2 [...]
Determining the Value of Continuous Glucose Monitoring
Continuous glucose monitoring (CGM) offers the potential for better diabetes management, but determining the value for patients, payers, and providers [...]
Investigating Value from the Perspective of Providers
With the ever-growing nurse and physician shortage and record levels of provider burnout, understanding the motivations of health care workers [...]
Oncology Care Model Reduces Medicare Costs for Cancer Treatment
A study evaluating the benefits of the Oncology Care Model, an alternate payment model for Medicare beneficiaries with cancer, found [...]
Unsubstantiated Drug-Price Hikes Identified by ICER
An ICER report examining the top ten drugs with 2020 price hikes found that a staggering seven out of ten [...]
Webinar: Biden, Congress, and Drug Prices
Drug pricing is being targeted by both the Biden administration and congress, according to a webinar now available on Research [...]
Germany’s Hybrid Model Fights High Prices
Germany’s hybrid private-public health insurance system may offer insights into lowering drug prices in the United States, according to a [...]
Value-based Pricing Programs Given Renewed Focus by Pfizer and Takeda
Value-based pricing and reimbursement models are not common in the United States, but this may change after recent programs by [...]
Insurers Refuse to Pay for New Alzheimer’s Drug Without Evidence of Efficacy
Twenty-five major insurers will not pay for Biogen’s Alzheimer’s drug Aduhelm without further proof of efficacy, according to results from [...]
Establishing the Value of Next-Gen Sequencing
Next-generation sequencing (NGS) has been touted by some as the backbone of future precision medicine approaches. This technology could help [...]
PhRMA President Introduces Recipients of 2020 Challenge Award, Emphasizes Commitment to Patient Centricity
The PhRMA Foundation has expanded its vision of the value assessment framework to include health equity and patient centricity. PhRMA [...]
PharmacoEconomics Article Authors Discuss 8 Recommendations for CEAs in Diagnostic Assessments
An article published in PharmacoEconomics details eight recommendations regarding how cost-effectiveness analyses (CEAs) are used in diagnostics. The researchers call [...]
ICER Releases Final Evidence Report for Hypertrophic Cardiomyopathy Drug
The Institute for Clinical and Economic Review (ICER) has published its Final Evidence Report for mavacamten, produced by MyoKardia and [...]
RWE Expert and Economist Details Future Global Market Access and Pricing Trends
Economist Ulf Staginnus shared his thoughts on future trends for market access and drug pricing in a recent discussion with [...]
CEVR Leaders Publish NEJM Article on Determining Value Using Cost-Effectiveness Analyses
Peter Neumann, Sc.D., Joshua Cohen, Ph.D., and Daniel Ollendorf, Ph.D. of the Center for the Evaluation of Value and Risk [...]